title: Molecular-targeted Therapy and Surgery May Prolong Survival of Renal Cell Carcinoma Patients with Bone Metastasis: A Multi-institutional Retrospective Study in Japan.
abstract: To determine prognostic factors for overall survival (OS) in renal cell carcinoma (RCC) patients with bone metastasis in the targeted-therapy era.
  
  
  
  We conducted a retrospective multi-institutional review of the medical records of 149 RCC patients with bone metastasis. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were performed to identify independent factors associated with OS.
  
  
  
  The median OS was 13.4 months. In multivariate analysis, molecular-targeted therapy, nephrectomy and surgery for bone metastasis were independent prognostic factors. Bone-modifying agents (BMAs) were not associated with OS. The median OS of patients receiving molecular-targeted therapy after diagnosis of bone metastasis was significantly better than that of those who did not receive targeted therapy.
  
  
  
  Molecular-targeted therapy, nephrectomy and surgery for bone metastasis should be considered for RCC patients with metastasis in the bones.
authors: Univerity of Toyama, Toyama, Japan hkitamur@med.u-toyama.ac.jp.
authors: Hiroshi
authors: H
authors: Kitamura
authors: Hakodate Goryoukaku Hospital, Hakodate, Japan.
authors: Atsushi
authors: A
authors: Takahashi
authors: Sunagawa City Medical Center, Sunagawa, Japan.
authors: Fumiyasu
authors: F
authors: Takei
authors: Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
authors: Hiroshi
authors: H
authors: Hotta
authors: Muroran City General Hospital, Muroran, Japan.
authors: Noriomi
authors: N
authors: Miyao
authors: NTT East Japan Sapporo Hospital, Sapporo, Japan.
authors: Tetsuya
authors: T
authors: Shindo
authors: Takikawa Municipal Hospital, Takikawa, Japan.
authors: Manabu
authors: M
authors: Igarashi
authors: Steel Memorial Muroran Hospital, Muroran, Japan.
authors: Hitoshi
authors: H
authors: Tachiki
authors: Obihiro Kyokai Hospital, Obihiro, Japan.
authors: Yasuharu
authors: Y
authors: Kunishima
authors: JCHO Hokkaido Hospital, Sapporo, Japan.
authors: Takashi
authors: T
authors: Muranaka
authors: Kushiro Red Cross Hospital, Kushiro, Japan.
authors: Masanori
authors: M
authors: Shigyo
authors: Oji General Hospital, Tomakomai, Japan.
authors: Yoshinori
authors: Y
authors: Ikehata
authors: Sapporo Medical University School of Medicine, Sapporo, Japan.
authors: Naoya
authors: N
authors: Masumori
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D007564:Japan; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
keywords: Kidney neoplasms; bone; molecular-targeted therapy; neoplasm metastasis; surgery